Pegylated liposomal doxorubicin in the management of ovarian cancer

References

• JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin20095922524919474385
   PubMed Web of Science ®Google Scholar
• EisenkopSMSpirtosNMFriedmanRLLinWCPisaniALPerticucciSRelative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective studyGynecol Oncol20039039039612893206
   PubMed Web of Science ®Google Scholar
• OzolsRFSystemic therapy for ovarian cancer: current status and new treatmentsSemin Oncol2006332 Suppl 6S3S1116716797
   PubMed Web of Science ®Google Scholar
• SalzbergMThurlimannBBonnefoisHCurrent concepts of treatment strategies in advanced or recurrent ovarian cancerOncology20056829329816020955
   PubMed Web of Science ®Google Scholar
• ArmstrongDKRelapsed ovarian cancer: challenges and management strategies for a chronic diseaseOncologist20027Suppl 5202812324630
   PubMed Web of Science ®Google Scholar
• ColomboNGoreMTreatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapyCrit Rev Oncol Haematol200764129138
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research [updated 2008 Oct 06]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050718s033lbl.pdfAccessed Dec 17, 2009
   Google Scholar
• GabizonAShmeedaHBarenholzYPharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studiesClin Pharmacokinet20034241943612739982
   PubMed Web of Science ®Google Scholar
• GabizonACataneRUzielyBProlonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomesCancer Res1994549879928313389
   PubMed Web of Science ®Google Scholar
• GabizonAIsacsonRRosengartenOTzemachDShmeedaHSapirRAn open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicinCancer Chemother Pharmacol2008469570217549475
   PubMedGoogle Scholar
• YokoeJSakuragiSYamamotoKAlbumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in ratsInt J Pharm2008353283418082345
   PubMed Web of Science ®Google Scholar
• BognerJRKronawitterURolinskiBTruebenbachKGoebelFDLiposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcomaJ Acquir Immune Defic Syndr199474634688158540
   PubMed Web of Science ®Google Scholar
• JamesNDCokerRJTomlinsonDLiposomal doxorubicin (Doxil): an effective new treatment for Kaposi’s sarcoma in AIDSClin Oncol (R Coll Radiol)199462942967530036
   PubMedGoogle Scholar
• UzielyBJeffersSIsacsonRLiposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studiesJ Clin Oncol199513177717857602367
   PubMed Web of Science ®Google Scholar
• JahanzebMVogelCElkrishMStealth liposomal doxorubicin (Doxil) causes a mild and delayed leukopenia compared to doxorubicin in patients with solid tumorsProc Am Soc Clin Oncol199716239 Abstr 843
   Google Scholar
• GabizonAUzielyBLotemMDoxil in patients with pretreated metastatic breast cancer (MBC): a dose-schedule finding study with pharmacokineticsProc Am Soc Clin Oncol199716147 Abstr 516
   Google Scholar
• CaponigroFComellaPBudillonAPhase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancerAnn Oncol20001133934210811502
   PubMed Web of Science ®Google Scholar
• HamiltonABiganzoliLColemanREORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with meta-static breast cancer. European Organization for Research and Treatment of CancerAnn Oncol20021391091812123337
   PubMed Web of Science ®Google Scholar
• MarinaNMCochraneDHarneyEDose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group studyClin Cancer Res2002841341811839657
   PubMed Web of Science ®Google Scholar
• HarrisonLEBryanMPlinerLSaundersTPhase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancyAnn Surg Oncol2008151407141318157576
   PubMed Web of Science ®Google Scholar
• KleinPWasserheitCHochsterHApparent protection of doxil skin and oral toxicities when combined with cisplatin (CDDP): results of a Phase I studyProc Am Soc Clin Oncol199918217 Abstr 835
   Google Scholar
• LyassOHubertAGabizonAAPhase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignanciesClin Cancer Res200173040304611595693
   PubMed Web of Science ®Google Scholar
• UysARapoportBLMahomedRPhase I trial of pegylated-liposomal doxorubicin (Caelyx, Doxil) and carboplatin in patients with advanced malignancyProc Am Soc Clin Oncol200221 Abstr 2138
   Google Scholar
• GoncalvesABraudACViretFPhase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumorsAnticancer Res2003233543354812926104
   PubMed Web of Science ®Google Scholar
• HamiltonALPavlickACVolmMPegylated liposomal doxorubicin (PLD) and carboplatin: a Phase I study of combination therapy with maintenance PLDProc Am Soc Clin Oncol200322 Abstr 1986
   Web of Science ®Google Scholar
• Gonzalez-BillalabeitiaEMendiolaCMelladoBfor the Grupo PSAMOMAA phase I/II clinical study of pegylated liposomal doxorubicin plus carboplatin in advanced ovarian cancerProc Am Soc Clin Oncol200322 Abstr 1919
   Google Scholar
• du BoisABurgesAMeierWArbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom. Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a pro-spective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)Ann Oncol200617939616282248
   PubMed Web of Science ®Google Scholar
• RecchiaFSaggioGAmiconiGA multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancerGynecol Oncol200710616416917481704
   PubMed Web of Science ®Google Scholar
• IsraelVKJeffersSBernalGPhase I study of doxil (liposomal doxorubicin) in combination with paclitaxelProc Am Soc Clin Oncol1998 Abstr 938
   Google Scholar
• MuggiaFMHornreichGWadlerSOverview of toxicities from a combination of Doxil-paclitaxel (PachiDox) in a New York Gynecologic Oncology Group (NYGOG) study on endometrial carcinomas and sarcomasProc Am Soc Clin Oncol2000 Abstr 1616
   PubMedGoogle Scholar
• ModianoMTaylorCSharpingtonTNgMMartinezAPhase I study of Doxil (pegylated liposomal doxorubicin) plus escalating doses of Taxol in the treatment of patients with advanced breast or gynecologic malignanciesProc Am Soc Clin Oncol1999 Abstr 848
   Google Scholar
• SchwonzenMKurbacherCMMallmannPLiposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancerAnticancer Drugs20001168168511129728
   PubMed Web of Science ®Google Scholar
• TolisCBriasoulisETzamakouEPhase I trial and interaction pharmacokinetics of pegylated-liposomal doxorubicin (Caelyx; Doxil) and weekly TaxolProc Am Soc Clin Oncol200019 Abstr 803
   Google Scholar
• AndroulakisNKouroussisCMavroudisDPhase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumoursEur J Cancer2002381992199712376203
   PubMed Web of Science ®Google Scholar
• MavroudisDKouroussisCKakolyrisSPhase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumorsOncology20026221622212065868
   PubMed Web of Science ®Google Scholar
• LortholaryADelozierTBourgeoisHA phase I study of paclitaxel in combination with pegylated liposomal doxorubicin (PLD) as second-line chemotherapy in metastatic breast cancer (MBC)Proc Am Soc Clin Oncol200322 Abstr 206
   Google Scholar
• BriasoulisEPentheroudakisGKaravasilisVWeekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumorsAnn Oncol2004151566157315367419
   PubMed Web of Science ®Google Scholar
• HirschRJahanzebMPhase I Study of Doxil in Combination with Escalating Doses of Taxotere in the Treatment of Patients with Advanced Malignancies (Meeting abstract)Proc Am Soc Clin Oncol1999 Abstr 820
   Google Scholar
• DrinkardLBlumenscheinGDiStefanoAAdamsJA Phase I trial of liposomal doxorubicin (Doxil) given on day one followed by docetaxel (Taxotere) given on day five in patients with advanced solid tumors. (Meeting abstracts)Proc Am Soc Clin Oncol199918 Abstr 801
   Google Scholar
• PavlickACChodkiewiczCLiebesLA phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factorAnticancer Drugs20041511912515075667
   PubMed Web of Science ®Google Scholar
• TauerKHusseinABirchRA phase i study of Taxotere (T) and Doxil (D) in refractory cancerProc Am Soc Clin Oncol200019 Abstr 901
   Google Scholar
• SparanoJAMalikURajdevLPhase I trial of pegylated iposomal doxorubicin and docetaxel in advanced breast cancerJ Clin Oncol200115;1931173125
   PubMed Web of Science ®Google Scholar
• SikovWMHsiehMLopezFPhase I weekly docetaxel with doxorubicin or Doxil: a BrUOG studyProc Am Soc Clin Oncol200120 Abstr 2088
   Google Scholar
• GaspariniGMorabitoAFanelliMPhase I–II study of liposomal doxorubicin and docetaxel as first-line treatment in patients with advanced breast cancerProc Am Soc Clin Oncol200221 Abstr 2029
   Web of Science ®Google Scholar
• FracassoPMRodriguezLCHerzogTJPhase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignanciesCancer20039861061712879480
   PubMed Web of Science ®Google Scholar
• BischoffJHesseSStemmlerHZaunerSGutschowKA phase I study of PEG liposomal doxorubicin (PLD) plus docetaxel (D) in metastatic breast cancer (MBC)Proc Am Soc Clin Oncol200322 Abstr 282
   PubMedGoogle Scholar
• EngCMauerAMFlemingGFMJ. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumorsAnn Oncol2001121743174711843253
   PubMed Web of Science ®Google Scholar
• RosePGGreerBEHorowitzIRMarkmanMFuscoNPaclitaxel, carboplatin, and pegylated liposomal doxorubicin in ovarian, and peritoneal carcinoma: A phase I study of the Gynecologic Oncology GroupGynecol Oncol200710411411916959305
   PubMed Web of Science ®Google Scholar
• GibbsDDPyleLAllenMA phase I dose-finding study of a combination of Pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancerBr J Cancer2002861379138411986767
   PubMed Web of Science ®Google Scholar
• RyanCWFlemingGFJanischLA phase I study of liposomal doxorubicin (Doxil) with topotecanAm J Clin Oncol20002329730010857898
   PubMed Web of Science ®Google Scholar
• YeungAWWongAAliMPhase I trial of doxil and topotecan in solid tumorsProc Am Soc Clin Oncol1998 Abstr 979
   Google Scholar
• HochsterHRosenthalMChachouaMSorichJMuggiaFProlonged topotecan infusion combined with doxil. a well tolerated regimenProc Am Soc Clin Oncol199918214 Abstr 822
   Google Scholar
• HamiltonAHoechsterHRosenthalMContinuous infusion topotecan (TP-CI) with Doxil (DX): a phase I study of dual topoisomerase inhibitionProc Am Soc Clin Oncol200019 Abstr 777
   Google Scholar
• GeertsenPFStr⊘yerIHerrstedtJWerner HansenSPhase I study of topotecan (T) and pegylated liposomal doxorubicin (Caelyx) in patients (pts) with progressive ovarian cancer within 12 months after first-line platinum-paclitaxel containing chemotherapyProc Am Soc Clin Oncol200120 Abstr 2522
   Google Scholar
• PautierPGermannNFaivreSPhase I study of Caelyx (KLX – stealth stabilized liposomal doxorubicin – Doxil) in combination with topotecan (TPT)Proc Am Soc Clin Oncol200019 Abstr 910
   Google Scholar
• MirchandaniDHochsterHHamiltonAPhase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancerClin Cancer Res2005115912591916115933
   PubMed Web of Science ®Google Scholar
• GarciaAARomanLMuderspachLPhase I clinical trial of topotecan and pegylated liposomal doxorubicinCancer Invest20052366567016377584
   PubMed Web of Science ®Google Scholar
• GhesquieresHFaivreSDjafariLPhase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignanciesInvest New Drugs20062441342116763786
   PubMed Web of Science ®Google Scholar
• RosePGSmrekarMHabaPFuscoNRodriguezMA phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancerAm J Clin Oncol20083147648018838885
   PubMed Web of Science ®Google Scholar
• PensonRTSeidenMVGoodmanAGynecologic Oncology Research Program at Dana Farber/Partners CancerCare. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignanciesGynecol Oncol200493370270715196868
   PubMedGoogle Scholar
• LaufmanLRSpiridonidisCHJonesJJRhodesVRossiKWallaceKPhase I study of Doxil and vinorelbine in patients with advanced malignanciesCancer Invest20042234435215493354
   PubMed Web of Science ®Google Scholar
• D’AgostinoGFerrandinaGGarganeseGPhase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancerOncology20026211011411914595
   PubMed Web of Science ®Google Scholar
• FracassoPMBlumKATanBRPhase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignanciesCancer2002952223222912412177
   PubMed Web of Science ®Google Scholar
• BozionelouVVamvakasLPappasPA dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumoursBr J Cancer200797434917551496
   PubMed Web of Science ®Google Scholar
• MuggiaFMHainsworthJDJeffersSPhase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulationJ Clin Oncol1997159879939060537
   PubMed Web of Science ®Google Scholar
• GordonANGranaiCORosePGPhase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancerJ Clin Oncol2000183093310010963637
   PubMed Web of Science ®Google Scholar
• RosePGMaxsonJHFuscoNLiposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosagesGynecol Oncol20018232332811531287
   PubMed Web of Science ®Google Scholar
• ArcuriCSorioRTognonGA phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinomaTumori20069055656115762356
   PubMed Web of Science ®Google Scholar
• KatsumataNFujiwaraYKamuraTPhase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology GroupJpn J Clin Oncol20083877778518927230
   PubMed Web of Science ®Google Scholar
• GorumluGKucukzeybekYKemal-GulMPegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patientsJ BUON200813334935218979548
   PubMed Web of Science ®Google Scholar
• SteppanIReimerDSeveldaUUlmerHMarthCZeimetAGTreatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin-an evaluation of the therapeutic index with special emphasis on cardiac toxicityChemotherapy20095539139819955744
   PubMed Web of Science ®Google Scholar
• ChouHHWangKLChenCA2005. Pegylated liposomal doxorubicin (Lipo-Dox(R)) for platinum-resistant or refractory epithelial ovarian carcinoma: A Taiwanese gynecologic oncology group study with long term follow-upGynecol Oncol200610142342816325239
   PubMed Web of Science ®Google Scholar
• MarkmanMKennedyAWebsterKPhase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneumGynecol Oncol2000783697210985896
   PubMed Web of Science ®Google Scholar
• CamposSMPensonRTMaysARThe clinical utility of liposomal doxorubicin in recurrent ovarian cancerGynecol Oncol20018120621211330951
   PubMed Web of Science ®Google Scholar
• WilailakSLinasmitaVA study of pegylated liposomal Doxorubicin in platinum-refractory epithelial ovarian cancerOncology20046718318615557776
   PubMed Web of Science ®Google Scholar
• LorussoDNaldiniATestaAPhase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?Oncology20046724323915557785
   PubMed Web of Science ®Google Scholar
• StraussHGHemsenAKarbeILautenschlägerCPersingMThomssenCPhase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancerAnticancer Drugs20081954154518418221
   PubMed Web of Science ®Google Scholar
• Oskay-OezcelikGKoensgenDHindenburgHJBiweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGOAnticancer Res2008281329133418505074
   PubMed Web of Science ®Google Scholar
• SehouliJOskay-OzcelikGKühneJBiweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trialAnn Oncol20061795796116600975
   PubMed Web of Science ®Google Scholar
• SehouliJCamaraOSchmidtMNorth-Eastern German Society of Gynecological Oncology. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational studyCancer Chemother Pharmacol20096458559119156414
   PubMed Web of Science ®Google Scholar
• ParmarMKLedermannJAColomboNICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer:the ICON4/AGO-OVAR-2.2 trialLancet20033612099210612826431
   PubMed Web of Science ®Google Scholar
• PfistererJPlanteMVergoteIAGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJ Clin Oncol2006244699470716966687
   PubMed Web of Science ®Google Scholar
• TasFDerinDGuneyNAydinerATopuzEChemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinumsensitive epithelial ovarian cancerInt J Clin Oncol20081333033418704633
   PubMed Web of Science ®Google Scholar
• VorobiofDARapoportBLSlabberCFPhase 2 study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancerProc Am Soc Clin Oncol200423471s
   Web of Science ®Google Scholar
• du BoisAPfistererJBurchardiNArbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom; Kommission Uterus. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut)Gynecol Oncol200710751852517910981
   PubMed Web of Science ®Google Scholar
• RapoportBLVorobiofDASlabberCPhase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancerInt J Gynecol Cancer2009191137114119820382
   PubMed Web of Science ®Google Scholar
• FerreroJMWeberBGeayJFSecond-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trialAnn Oncol20071826326817108151
   PubMed Web of Science ®Google Scholar
• PowerPStuartGOzaAEfficacy of pegylated liposomal doxorubicin (PLD) plus carboplatino in ovarian cancer patients who recur within six to twelve months: a phase II studyGynecol Oncol200911441041419520420
   PubMed Web of Science ®Google Scholar
• WeberBLortholaryAMayerFPegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trialAnticancer Res2009294195420019846972
   PubMed Web of Science ®Google Scholar
• NicolettoMOFalciCPianaltoDPhase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancerGynecol Oncol200610031832316239023
   PubMed Web of Science ®Google Scholar
• RecchiaFDe FilippisSSaggioGPhase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancerAnticancer Drugs20031463363814501385
   PubMed Web of Science ®Google Scholar
• ValerioMRTagliaferriPRaspagliesiFA phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinomaInt J Gynecol Cancer200616Suppl 1798516515572
   PubMedGoogle Scholar
• SmithHOMoonJWilczynskiSPSouthwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancerGynecol Oncol200911420620919464730
   PubMed Web of Science ®Google Scholar
• TasFGuneyNDerinDAydinerATopuzEA pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancerInt J Clin Oncol20081315616018463961
   PubMed Web of Science ®Google Scholar
• SkarlosDVKalofonosHPFountzilasGGemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II studyAnticancer Res2005253103310816080573
   PubMed Web of Science ®Google Scholar
• HollowayRWFinklerNJNyeLPDoxil and gemcitabine combination therapy for recurrent ovarian cancer: results of a phase II trialProc Am Soc Clin Oncol2004 Abstr 5090
   Google Scholar
• KaraogluAArslanUYOzkanMEfficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancerAsian Pac J Cancer Prev200910636619469626
   PubMed Web of Science ®Google Scholar
• PetruEAngleitner-BoubenizekLReinthallerACombined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: A phase II Austrian AGO studyGynecol Oncol2006101182316330088
   PubMedGoogle Scholar
• D’AgostinoGFerrandinaGLudovisiMPhase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancerBr J Cancer2003891180118414520442
   PubMed Web of Science ®Google Scholar
• FerrandinaGParisILudovisiMGemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survivalGynecol Oncol20059826727315975643
   PubMed Web of Science ®Google Scholar
• TanyiJLSmithJARamosLParkerCLMunsellMFWolfJKPredisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancerGynecol Oncol200911421922419446868
   PubMed Web of Science ®Google Scholar
• Verhaar-LangereisMKarakusAvan EijkerenMPhase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancerInt J Gynecol Cancer200616657016445612
   PubMed Web of Science ®Google Scholar
• CamposSMMatulonisUAPensonRT2003. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumorsGynecol Oncol20039061061813678734
   PubMed Web of Science ®Google Scholar
• KatsarosDOlettiMVRigault de la LongraisIAClinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinomaAnn Oncol20051630030615668288
   PubMed Web of Science ®Google Scholar
• JolyFSevinELortholaryAAssociation of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A multicenter phase II trialGynecol Oncol2009112 [Epub ahead of print)
   Web of Science ®Google Scholar
• O’ByrneKJBlissPGrahamJDA Phase III study of Doxil/Caylex versus paclitaxel in platinum treated taxane naive relapsed ovarian cancerProc Am Soc Clin Oncol200221 Abstr 808)
   Google Scholar
• GordonANFleagleJTGuthrieDParkinDEGoreMELacaveAJRecurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecanJ Clin Oncol2001193312332211454878
   PubMed Web of Science ®Google Scholar
• GordonANTondaMSunSRackoffWLong-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecol Oncol2004951815385103
   PubMed Web of Science ®Google Scholar
• MutchDGOrlandoMGossTRandomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerJ Clin Oncol2007252811281817602086
   PubMed Web of Science ®Google Scholar
• FerrandinaGLudovisiMLorussoDPhase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancerJ Clin Oncol20082689089618281662
   PubMed Web of Science ®Google Scholar
• SatyamAHockerMDKane MaguireKAMorganASVillarHOLyttleMHDesign, synthesis and evalution of latent alkylating agents activated by glutathione S-transferaseJ Med Chem199639173617478648613
   PubMed Web of Science ®Google Scholar
• VergoteIFinklerNdel CampoJPhase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancerEur J Cancer2009452324233219515553
   PubMed Web of Science ®Google Scholar
• VergoteIFinklerJHallJBRandomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC)Proc Am Soc Clin Oncol2009 Abstr 5552
   Google Scholar
• GanjooKNPatelSRTrabectedin: an anticancer drug from the seaExp Opin Pharmacother20091027352743
   PubMed Web of Science ®Google Scholar
• von MehrenMSchilderRJChengJDA phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignanciesAnn Oncol2008191802180918497430
   PubMed Web of Science ®Google Scholar
• McMeekinSDel CampoJMColomboNTrabectedin (T) in relapsed advanced ovarian cancer (ROC): a pooled analysis of three phase II studiesProc Am Soc Clin Oncol200725 18sAbstr 5579
   Google Scholar
• MonkBJHerzogTKayeSA randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed ovarian cancer (OC)2008Proceedings of ESMO; Ann Oncol19 9Abstr LBA4
   Google Scholar
• KrasnerCNPovedaAHerzogTHealth-related quality of life/patient-reported outcomes in relapsed ovarian cancer: results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD aloneProc Am Soc Clin Oncol200927 15sAbstr 5526
   Web of Science ®Google Scholar
• AlbertsDSLiuPYWilczynskiSPRandomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin in platinum sensitive (PS) patients with recurrent epithelial ovarian or peritoenal carcinoma after failure of initial platinum-based chemotherapy (South-west Oncology Group Protocol S0200)Gynecol Oncol2008108909417949799
   PubMed Web of Science ®Google Scholar
• MarkmanMMoonJWilczynskiSSingle agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trialGynecol Oncol20091229 [Epub ahead of print]
   Web of Science ®Google Scholar
• LinardouHBafaloukosDBamlasAA randomized, Phase II study of carboplatin plus liposomal doxorubicin (CLD) vs carboplatin plus paclitaxel (CP) in potentially platinum sensitive ovarian cancer patients. A Hellenic Cooperative Oncology GroupEur J Cancer20075Suppl 3122Abstr 5003
   Google Scholar
• Pujade-LauraineEMahnerSKaernJA randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)J Clin Oncol20092718s suppl Abstr LBA5509
   Google Scholar
• VaseyPLargillierRGroppMA GCIC randomized phase III study of carboplatin © and pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin and paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC)Proc ESMO2009 Abstr LBA18
   Google Scholar
• PotamianouAAndroulakisNPapakotoulasPSequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trialOncology20056934835316293974
   PubMed Web of Science ®Google Scholar
• BookmanMABradyMFMcGuireWPEvaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer IntergroupJ Clin Oncol200920;2714191425
   Web of Science ®Google Scholar
• PignataSScambiaGSavareseAMITO InvestigatorsSafety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trialBMC Cancer2006620216882344
   PubMed Web of Science ®Google Scholar
• PignataSScambiaGSavareseACarboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trialOncology200976495419039248
   PubMed Web of Science ®Google Scholar
• PignataSScambiaGSavareseACarboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer: activity and safety results of the MITO-2 randomised multicenter trialsProc Am Soc Clin Oncol200927 LBA 5508
   Web of Science ®Google Scholar
• Sánchez-MuñozAPérez-RuizEMendiola FernándezCAlba ConejoEGonzález-MartínACurrent status of anti-angiogenic agents in the treatment of ovarian carcinomaClin Transl Oncol20091158959519775998
   PubMed Web of Science ®Google Scholar
• MuggiaFMBoydLLiebesLPegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): pharmacokinetics (PK), safety, and preliminary outcome resultsProc Am Soc Clin Oncol2009 Abstr 5548
   Google Scholar
• KikuchiYKoutaHKikuchiEffects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancerProc Am Soc Clin Oncol2009 Abstr 5547
   Web of Science ®Google Scholar
• RamakrishnanVBhaskarVLawDAPreclinical evaluation of an anti alpha5beta1 integrin antibody as a novel antingiogenic agentJ Exp Ther Oncol2006527328617024968
   PubMedGoogle Scholar
• VergoteIColomboNKutarskaEPhase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancerProc Am Soc Clin Oncol2009 Abstr 5560
   Web of Science ®Google Scholar
• DeesECO’NeilBHLindleyCMPhase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumorsCancer Chemother Pharmacol2008639910718327587
   PubMed Web of Science ®Google Scholar
• ScambiaGParmaGDel ConteDA phase II combination study of bortezomib with pegylated-liposomal doxorubicin in patients with ovarian cancer failing platinum containing regimensProc Am Soc Clin Oncol2008 Abstr 5581
   Web of Science ®Google Scholar
• O’BrienMEWiglerNInbarMReduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancerAnn Oncol20041544044914998846
   PubMed Web of Science ®Google Scholar
• MartschickASehouliJPatzeltAPathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesiaAnticancer Res2009292307231319528496
   PubMed Web of Science ®Google Scholar
• JacobiUWaiblerESchulzePRelease of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?Ann Oncol2005161210121115857845
   PubMed Web of Science ®Google Scholar
• GordinierMEDizonDSFlemingELElevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicinGynecol Oncol2006103727416494932
   PubMed Web of Science ®Google Scholar
• LyassOUzielyBBen-YosefRCorrelation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinomaCancer2000891037104710964334
   PubMed Web of Science ®Google Scholar
• MolpusKLAndersonLBCraigCLPuleoJGThe effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinomaGynecol Oncol20049351351615099971
   PubMed Web of Science ®Google Scholar
• LorussoDDi StefanoACaroneVFagottiAPiscontiSScambiaGPegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome)Ann Oncol2007181159116417229768
   PubMed Web of Science ®Google Scholar
• Von GruenigenVEFrasureHFuscoNA double-blind ranodmized trial of pyridoxine versus placebo fort he prevention of pegylated liposomal doxorubicin hydrochloride-related palamr-plantar erythrodysesthesiaProc Am Soc Clin Oncol2009 Abstr 5594
   Web of Science ®Google Scholar
• ColemanREBiganzoliLCanneyPA randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)Eur J Cancer20064288288716520033
   PubMed Web of Science ®Google Scholar
• von MoosRThuerlimannBJAaproMPegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of expertsEur J Cancer20084478179018331788
   PubMed Web of Science ®Google Scholar